Posts Archive

NCT00478218: Phase 2 : Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma...

NCT00573391: Phase 3: Study of Multiple Myeloma Patients Relapsing or Progressing After Autologous Transplantation on Total Therapy 2...

UPFRONT NCT00507416: Phase 3: Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and...

Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma The purpose of this...

SUMMIT, N.J., June 29, 2006 /PRNewswire/ -- Celgene Corporation (Nasdaq: CELG) announced that the U.S. Food and Drug Administration (FDA)...

IFM 99-06 NCT00367185: Phase 3 - Treatment of Newly Diagnosed Elderly Patients With Multiple Myeloma In multiple myeloma, combination...

MM-015 study NCT00405756 A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older. The purpose...

CALGB 100104 Lenalidomide in Treating Patients With Multiple Myeloma Undergoing Autologous Stem Cell Transplant NCT00114101: Phase 3 -...

Phase 3 VISTA Study phase III VISTA trial (Velcade As Initial Standard Therapy in Multiple Myeloma: Assessment With Melphalan and...

IFM 2005-01: Velcade/Dexamethasone Versus Vincristine/Adriamycin (Doxorubicin)/Dexamethasone (VAD) for the Treatment of Patients With...

This study has been designed to evaluate whether "anti-angiogenesis" therapy with thalidomide and whether additional chemotherapy after...

UARK 2003-33, Total Therapy III Total Therapy 3 The UARK 2003-33, Total Therapy III - There have been two previous Total Therapy studies...

ECOG-ACRIN Cancer Research Group ECOG E4A03 NCT00098475: Phase 3: Lenalidomide and Dexamethasone With or Without Thalidomide in Treating...

N Engl J Med May 24, 1984 Effective treatment of advanced multiple myeloma refractory to alkylating agents. Barlogie B, Smith L,...

RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Thalidomide may...

IFM - Time Frame: October 1994 and March 1997 IFM (Intergroupe Francophone du Myelome) N Engl J Med, 2003 Dec 25 Single versus double...

Multiple Myeloma (009) MM-009 NCT00056160 : Phase 3 - CC-5013 Plus Dex Versus Dex Alone in Previously Treated Subjects With Multiple...

On May 13, 2003, the U.S. Food and Drug Administration (FDA) granted accelerated approval for bortezomib (formerly PS-341), Velcade....

Phase 3 - PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma NCT00048230 This...

(Intergroupe Francophone du Myélome [IFM] 9502 trial) Time Frame: July 1995 to January 1999 IFM 9502 trial: 200 mg/m(2) melphalan Vs 8...

IFM - (Intergroupe Francophone du Myélome) Time Frame: October 1990 and May 1993 IFM trial: Conventional chemo or high-dose therapy and...

Time Frame: December 1997 and June 1998 Phase 2: Antitumor Activity of Thalidomide in Refractory Multiple Myeloma - NEJM 1999 Antitumor...

Time Frame: August 1990 and August 1995 Total therapy with tandem transplants for newly diagnosed multiple myeloma Blood; 1999 B Barlogie...

Time Frame: October 1996 and October 2000 Results of autologous stem cell transplant in multiple myeloma patients with renal failure...